Venture pro Shermaine Tilley joins Immunovaccine's board
Shermaine Tilley, a managing partner at CTI Life Sciences Fund, has been nominated to serve on the board of Immunovaccine Inc (TSX: IMV), a Halifax-based developer of cancer immunotherapies and infectious disease vaccines. Tilley joined CTI, a Montréal-based venture capital firm, at its inception in 2006. She was previously a senior vice president at Canadian private equity firm DRI Capital. CTI was an investor in the $127 million Series B financing raised by DalCor Pharmaceuticals in April.
10 June 2016•6 mins read
